Evotec Announces the Expansion of its GMP Sterile Pharmaceutical Manufacturing Facility
News Jul 17, 2007
Evotec AG has announced the expansion of its sterile pharmaceutical manufacturing facility in Glasgow, Scotland. The Company has doubled its capacity for the aseptic (sterile) GMP manufacture of pharmaceuticals to be used in clinical trials with the new facility being operational with immediate effect.
Evotec’s formulations business is a niche provider of contract pharmaceutical development services for the development of formulations of pharmaceuticals intended for parenteral administration and the manufacture of formulated drugs for use in Phase I and Phase II clinical trials.
The expansion of the facilities is in response to the demand from its clients for clinical supplies of liquid and lyophilised drug product. Evotec has demonstrated its expertise in drug formulation development and sterile manufacturing, offering its clients services of the highest quality and technical standards.
These additional facilities will allow Evotec to shorten the lead-time to access its manufacturing capabilities. This will therefore accelerate the progression of Evotec’s clients’ drugs into the clinical stage of drug development.
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE